Applied Sciences Webinar | Plasma-Chemical Processes for Combined Cancer Therapies
the chairs
We are pleased to invite you to participate in an in-depth webinar on “ Plasma-Chemical Processes for Combined Cancer Therapies”.
This event is organized within the framework of the projects entitled “Bi-functioNal plasma-treated solutions as a new thErapeutiC Tool for cAnceR (NECTAR)”, funded by the European Union’s NextGeneration EU instrument through the project PRIN PNRR 2022-P2022F4P8P, and “COld atmospheric plasma therapy to target head and neck Tumours by A multImodaL approach (Cocktail)”, also funded by NextGenerationEU (MUR, Fondo Promozione e Sviluppo, DM 737/2021—CUP number: D75F21003210001). The webinar will provide a comprehensive overview of how plasma technology is being integrated as an adjunctive tool to enhance the efficacy of conventional cancer treatments. Leading experts will present the latest research, discuss clinical implications, and explore the future potential of plasma applications in oncology. This webinar is tailored for healthcare professionals, researchers, researchers, chemists, physicists, and engineers working in the field of plasma medicine.
Date: 16 December 2024
Time: 10:15 am (CET) - Updated
Webinar ID: 820 9647 9691
Webinar Secretariat: journal.webinar@mdpi.com
Meet the Event Chairs
Meet Our Speakers
Prof. Michael Keidar
A. James Clark Professor of Engineering
Department of Mechanical and Aerospace Engineering
Department of Biomedical Engineering
School of Engineering and Applied Science
The George Washington University
Washington, DC 20052, USA;
Michael Keidar is A. James Clark Professor of Engineering at the George Washington University. His research concerns plasma physics and engineering with application in advanced spacecraft propulsion, plasma medicine,
and plasma-based nanotechnology. He has authored over 340 journal articles and 330 conference papers, and he is the author of the textbook “Plasma Engineering” and the book “Plasma Cancer Therapy”. He received the 2017 Davidson award in plasma physics; in 2016, he received the AIAA Engineer of the Year award for his work on micropropulsion, resulting in the successful launch of a nanosatellite with thrusters developed by his laboratory; and he received the Plasma Medicine Award in 2021. Prof. Keidar serves as Editor-in-Chief of Journal of Electric Propulsion, AIP Advances academic editor, Associate Editor of IEEE Transactions in Radiation and Plasma Medical Sciences, and member of the Editorial Board of half-a-dozen journals. He is an elected Fellow of the National Academy of Investors, Fellow of the American Physical Society, and Fellow of the American Institute of Astronautics and Aeronautics. He is the elected President of the Electric Rocket Propulsion Society.
Prof. Nagendra Kumar Kaushik
Department of Electrical and Biological Physics & Plasma Bioscience Research Center, Kwangwoon University, Seoul 01897, South Korea;
Nagendra Kaushik is a Professor at Kwangwoon University, where he has served for the last 14 years. He also holds an Honorary Professorship at MSB University (State University), India. He is one of the founding members of Plasma Bioscience Research Center and holds the Vice Director position.
Renowned for his research in plasma bioscience, nanobiotechnology, and biomaterials, Prof. Kaushik has published over 250 papers and has applied for multiple patents. He is a Highly Cited Researcher of Kwangwoon University, placing him in the top 1% of researchers, and serves as an Editor for over 20 leading journals. Prof. Kaushik has been listed in the World's Top 2% Scientists by Stanford University and Elsevier for the last four consecutive years.
He has also been honored with the Fellow of Royal Society of Chemistry (FRSC) UK, Early Career Plasma Medicine Award from the International Society of Plasma Medicine, and recognized as the "Sunlight of Korea" by the BRIC organization, and many other awards for his high-impact academic and industrial research.
Prof. Sander Bekeschus
ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489, Greifswald, Germany, Department of Dermatology and Venerology, Rostock University Medical Center, 18057, Rostock, Germany;
Sander Bekeschus is a human biologist and trained immunologist who has been active since the very early days of plasma biomedical sciences in 2010. In 2016, he founded the PRE research group at ZIK plasmatis (INP, Greifswald, Germany), which has since published more than 100 articles, including many in high-impact journals, being among the most productive plasma medicine teams worldwide. Sander’s work has been key in linking plasma science with reactive species (redox) biology and medicine research, immunology, dermato-oncology, and plasma-treated liquids. He is the holder of the Plasma Medicine Society and Society for Free Radical Research Young Investigator Awards. Currently, he heads the Research Program PLASMA MEDICINE (INP) and is Professor for TRANSLATIONAL PLASMA RESEARCH at Rostock University Medical Center in Germany, besides being an Executive Board Member of the International Workshop on Plasma Cancer Treatment (IWPCT) and the International Society for Plasma Medicine (ISPM). Sander oversees a research team of more than 20 members in two locations and is the Initiator and Speaker of the First European Marie-Curie Doctoral Training School in Plasma Medical Science, plasmACT.
Prof. Evelien Smits
Center for Oncological Research, University of Antwerp, Belgium;
Evelien Smits is Full Professor at the University of Antwerp, head of the Center for Oncological Research (CORE), chair of the Department and co-founder of the recognized research excellence consortium with 9 promotors and more than 100 research members, the Integrated Personalized and Precision Oncology Network (IPPON;www.uantwerp.be/ippon). Her own research team on tumor immunology and cancer immunotherapy consists of 3 full-time postdocs, 14 PhD students and 4 lab technicians.
The strategic mission of her research is to improve the quality-of-life and the lifespan of cancer patients by increasing the applicability of immunotherapy, both in terms of number of responsive cancer types and number of responsive patients. Therefore, Evelien Smits has got a passion for developing novel immunotherapeutic strategies to treat cancer by combining immune activation and tackling immunosuppression. Her three major research lines are on 1) plasma oncology; 2) immune checkpoints; and 3) natural killer cell therapy. In addition, she is co-principal investigator of 3 ongoing academic investigator-driven cell therapy studies at the Center for Cell Therapy and Regenerative Medicine at the Antwerp University Hospital. Her research comprises the full spectrum from basic research till clinical studies and she has proven to be able to bring new discoveries from the bench to the bedside. She has got 165 Web of Science-indexed articles (h-index 50; 9000 citations). Amongst other prizes, in 2017 Evelien Smits received theFWO/FNRS AstraZeneca Foundation Award for her research achievements in the domain of immunotherapy with regard to characterization of the tumor immune microenvironment and investigation of novel combination strategies in different cancers, both preclinically and clinically. Amongst others, she is involved in theHorizon Europe CANCERNA consortium project and the MSCA Doctoral Network PlasmACT and she is member of the EU COST PlasTHER and EU COST IMMUNO-model.
Sponsors and Partners
Organizer
The webinar was hosted via Zoom and required registration to attend. The full recording can be found below. In order to learn about future webinars, you can sign up to our newsletter by clicking “Subscribe”.